Get the Stockscreener App
0.00
100.00%
-1.17
Ocuphire Pharma Inc stock is traded at $0.00, with a volume of 0.
It is down -100.00% in the last 24 hours and down -100.00% over the past month.
Ocuphire Pharma Inc is a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Ocuphire's pipeline includes two small molecular product candidates targeting the front and back of the eye indications. The Nyxol candidate is being developed for dim light or night vision disturbances, reversal of pharmacologically induced mydriasis, and presbyopia. The second product candidate, APX3330, is being developed for diabetic retinopathy and diabetic macular edema.
See More
Previous Close:
$1.17
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$30.65M
Revenue:
$16.45M
Net Income/Loss:
$-14.11M
P/E Ratio:
0.00
EPS:
0.84
Net Cash Flow:
$-11.46M
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-100.00%
1-Day Range:
$0.00
$0.00
1-Week Range:
$0.00
$0.00
52-Week Range:
$0.00
$3.3994
Ocuphire Pharma Inc Stock (OCUP) Company Profile
Name
Ocuphire Pharma Inc
Sector
Industry
Phone
248-681-9815
Address
37000 GRAND RIVER AVE., FARMINGTON HILLS
Ocuphire Pharma Inc Stock (OCUP) Latest News
The RD Fund Announces Ocuphire Pharma's Acquisition of Opus Genetics - Lelezard
Ocuphire Pharma Acquires Opus Genetics - Marketscreener.com
North Carolina gains public company with merger - The Business Journals
Ocuphire buys Opus Genetics, grows gene therapy pipeline - The Pharma Letter
Ocuphire Pharma Announces Acquisition of Opus Genetics - Vision Monday
Ophthalmic Biopharmaceutical Ocuphire Pharma Shifts Focus To Gene Therapy Through Opus Genetics Stock Deal - AOL
Ocuphire Pharma Merges with Opus Genetics, Renamed Opus Genetics - Yahoo Finance
OCUP stock touches 52-week low at $1.14 amid market challenges - Investing.com UK
Ocuphire and Opus Genetics merge to develop IRD gene therapy - Yahoo! Voices
Shareholder Alert: Ademi LLP Investigates Whether Ocuphire Pharma, Inc. Is Breaching Its Duties to Its Public Shareholders - Business Wire
Ocuphire Pharma acquires Opus Genetics in all-stock deal By Investing.com - Investing.com Australia
Ocuphire Pharma acquires Opus Genetics - MSN
Wilson Sonsini Advises Opus Genetics on IP Matters Related to Acquisition by Ocuphire Pharma - Wilson Sonsini
Ocuphire Pharma acquires Opus Genetics in all-stock deal - Investing.com
Presbyopia Market on Track for Major Expansion by 2034, - openPR
Presbyopia Market on Track for Major Expansion by 2034, According to DelveInsight | Eyenovia, Orasis Pharma, Ocuphire Pharma, Novartis, Visus Therapeutics - The Globe and Mail
Mydriasis Market Forecasted to Surge in Coming Years, 2024-2034 - openPR
Ocuphire reports positive phase 3 results for eye treatment RYZUMVI - Investing.com
Ocuphire Pharma releases results from MIRA-2 and MIRA-3 clinical trials for phentolamine ophthalmic solution 0.75% for pharmacologically-induced mydriasis - Ophthalmology Times
Ocuphire reports positive phase 3 results for eye treatment RYZUMVI By Investing.com - Investing.com South Africa
Ocuphire Pharma Announces Publication of Full Phase 3 - GlobeNewswire
Ocuphire Pharma Announces Publication of Full Phase 3 Results of Phentolamine Ophthalmic Solution 0.75% for Pharmacologically-Induced Mydriasis in Ophthalmology - StockTitan
OFS Credit Company, Inc. Prices Preferred Stock Offering - Business Wire
Ocugen Inc. stock falls Tuesday, underperforms market - MarketWatch
OFS Credit to offer preferred stock in public offering - MSN
Ratio Review: Analyzing Ocugen Inc (OCGN)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
Analyzing SOPHiA GENETICS (NASDAQ:SOPH) & Cyclo Therapeutics (NASDAQ:CYTH) - Defense World
Oaktree Specialty Lending director buys shares worth over $16,000 By Investing.com - Investing.com Canada
Is OCGN’s price to cash per share ratio a concern for investors? - US Post News
Option Care Health, Inc. (NASDAQ:OPCH) Position Increased by First Eagle Investment Management LLC - Defense World
Option Care Health, Inc. (NASDAQ:OPCH) Shares Sold by DekaBank Deutsche Girozentrale - Defense World
Halozyme's ENHANZE® (HALO) Technology Empowers OCREVUS ZUNOVO™: A New Era in MS Treatment - BP Journal
Opaleye Management Inc. Increases Stake in Codexis Inc. - Yahoo Finance
All the Doctor Odyssey guest stars we know so far - Hidden Remote
Mydriasis Treatment Market Booming Worldwide With Leading Key - openPR
Full approval of PBC therapy Ocaliva rejected by FDA committee in 10-1 vote - Liver Disease News
American Century Companies Inc. Raises Position in Option Care Health, Inc. (NASDAQ:OPCH) - Defense World
Roche’s injectable Ocrevus Zunovo granted FDA approval to treat relapsing and primary MS - PMLiVE
Ocuphire Pharma, Inc. (OCUP) Reports Q2 Loss, Lags Revenue Estimates - MSN
Ocuphire Pharma commences phase 3 trial for presbyopia treatment - Investing.com India
UPDATE – Ocuphire Pharma Initiates VEGA-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% for Presbyopia - Yahoo Finance UK
UPDATE – Ocuphire Pharma Initiates VEGA-3 Phase 3 Trial - GlobeNewswire
Ocuphire Pharma Initiates VEGA-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% for Presbyopia - StockTitan
Ocuphire Pharma Inc [OCUP] Chief Scientific & Dev. Ofc. makes an insider purchase of 3,500 shares worth 6178.0. - Knox Daily
OCUP stock touches 52-week low at $1.15 amid market challenges - Investing.com
Analysts review Ocuphire Pharma Inc’s rating - Knox Daily
There is no way Ocuphire Pharma Inc (OCUP) can keep these numbers up - SETE News
Ocuphire Pharma Inc (OCUP) stock: A year of ups and downs - US Post News
Ocuphire Pharma Inc Stock (OCUP) Financials Data
Revenue
Net Income
Cash Flow
EPS
Ocuphire Pharma Inc Stock (OCUP) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Magrath George | Chief Executive Officer |
May 17 '24 |
Buy |
1.75 |
5,000 |
8,772 |
430,000 |
| SCHACHLE JOSEPH K | Chief Operating Officer |
Mar 21 '24 |
Buy |
2.05 |
2,000 |
4,100 |
2,000 |
| Jhaveri Nirav S. | Chief Financial Officer |
Mar 21 '24 |
Buy |
2.10 |
10,000 |
21,000 |
150,000 |
| Magrath George | Chief Executive Officer |
Mar 18 '24 |
Buy |
1.96 |
25,000 |
49,050 |
425,000 |
1.75%
0.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):